Shaily Engineering Plastics Q1 FY27: Healthcare Drives Robust Revenue Growth

Shaily Engineering Plastics reported Q1 FY27 revenue of INR 281 crore, marking a 14% increase year-on-year. Profit after tax (PAT) grew 17% to INR 48 crore.

Reader Takeaway: Healthcare segment boom offsets consumer slowdown; capacity expansion poised for future growth.

What just happened

Shaily Engineering Plastics announced its first-quarter results for FY27, with consolidated revenue reaching INR 281 crore, up from INR 247 crore in the same period last year. EBITDA saw an 18% increase to INR 83 crore, and PAT rose by 17% to INR 48 crore. The EBITDA margin improved by 120 basis points to 29.7%, and PAT margin increased by 40 basis points to 17.1%.

Why this matters

The strong revenue growth was primarily fueled by the company's Healthcare segment, which experienced an exceptional 85% year-on-year increase, now becoming the largest contributor to revenue at 51%. This segment's performance, driven by pen injectors for chronic therapies like GLP-1, significantly compensated for a 24% decline in the Consumer segment. The results indicate a successful diversification and a growing reliance on higher-margin medical devices.

The backstory

Shaily Engineering Plastics has been strategically shifting its focus towards the high-growth Healthcare sector, particularly in medical devices like pen injectors. This move comes as the traditional Consumer segment faces demand challenges in key export markets like Europe and the U.S.

What changes now

The company is aggressively expanding its pen manufacturing capacity, with an additional 25 million units expected by September 2026. Investments are also planned for semiconductor trays and a new plant in Southern India. The Abu Dhabi plant is slated to begin commercial sales by FY28.

Risks to watch

The Consumer segment's revenue decline of 24% highlights ongoing softness in European and U.S. markets, with management expecting similar performance this fiscal year. The execution of capacity expansions and the ramp-up of new components for consumer electronics carry inherent risks. Geopolitical tensions impacting commodity and freight costs remain a watchpoint, though management expects normalization by Q3 FY27.

Peer comparison

While specific peer data for this quarter's filing is not provided, Shaily's focus on the high-growth medical device components market, especially pen injectors for chronic diseases like GLP-1, positions it in a segment with significant global demand. Competitors in this niche would likely include global medical device manufacturers and contract manufacturers specializing in drug delivery systems.

Context metrics (time-bound)

• Pen Capacity: Production reached nearly 9 million pens in Q1 FY27. Total installed capacity is expected to reach approximately 75 million pens per annum post-expansion.
• New Plant Investment: INR 80-100 crore planned for a new facility in Southern India.
• Semiconductor Trays: Approximately INR 5 crore investment planned.

What to track next

Investors will be closely watching the ramp-up of new pen production lines, the commercialization of new components for consumer electronics, and the progress of the new Southern India plant. Management's guidance on exceeding pen volume targets and achieving gross margin normalization in Q3 FY27 will also be key.